The Manila Times

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Ann…

For patients across all indications treated within the RP2D range early, promising progression-free survival (PFS) and ...